The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

FDA expands Jemperli + chemo approval to all adults with primary advanced or recurrent endometrial cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE

FDA has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Clinical Roundup

Phase III Blenrep trial in multiple myeloma produces positive topline results

An interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma, showed that the trial met its primary endpoint of progression-free survival at a prespecified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee.
Clinical Roundup

Jemperli + Zejula improved PFS in advanced or recurrent endometrial cancer in RUBY Part 2 phase III trial

In a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer, the trial met its primary endpoint of progression-free survival.
Clinical Roundup

Phase III trial of Jemperli + chemo meets endpoint of OS in primary advanced or recurrent endometrial cancer

Part 1 of the phase III RUBY trial of Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel) followed by dostarlimab as a single agent, compared to placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer produced positive primary results from a planned analysis.
Clinical Roundup

DUO-E phase III trial: Imfinzi + Lynparza reduces risk of progression/death vs. chemo in advanced/recurrent endometrial cancer

Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer. 

Login

Site license subscribers:
Log in with your IP | Register a sponsored account